IP Library › Granted Patent US 8,835,610

Granted Patent B2

US 8,835,610 · App. 12/718,841 · Granted Sep 16, 2014

IL-17 binding proteins

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 8,835,610
App. No.: 12/718,841
Granted: Sep 16, 2014
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

Proteins that bind IL-17 and/or IL-17F are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Claims (446)

1. An antibody or antigen binding portion thereof comprising an antigen binding domain, wherein the antibody or antigen binding portion thereof binds human IL-17, and the antigen binding domain comprises six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein:

CDR-H1 has an amino acid sequence S-Y-G-I-S (residues 31-35 of SEQ ID NO:46) or a modification of said amino acid sequence by a substitution of at least one amino acid residue, wherein:

the substitution of S at position 1 is selected from the group consisting of G, T, V, and R;

the substitution of G at position 3 is selected from the group consisting of D, V, S, A, C, and I;

the substitution of I at position 4 is selected from the group consisting of F, T, Y, M, and V; and

the substitution of S at position 5 is selected from the group consisting of G, C, N, V, and H;

CDR-H2 has an amino acid sequence G-I-T-P-I-L-G-T-A-N-Y-A-Q-K-F-Q-G (residues 50-66 of SEQ ID NO:46) or a modification of said amino acid sequence by a substitution of at least one amino acid residue, wherein:

the substitution of I at position 2 is V;

the substitution of P at position 4 is selected from the group consisting of H, N, T, L, I, V, S, and F;

the substitution of I at position 5 is selected from the group consisting of F, I, M, V, S, and L;

the substitution of L at position 6 is F;

the substitution of G at position 7 is selected from the group consisting of M, L, E, and A;

the substitution of T at position 8 is selected from the group consisting of I, S, W, A, F, L, M, V, and H;

the substitution of A at position 9 is selected from the group consisting of T, V, S, E, D, P, I, G, and R;

the substitution of N at position 10 is selected from the group consisting of D, Y, S, T, V, and I; and

the substitution of G at position 17 is D;

CDR-H3 has an amino acid sequence E-P-N-D-F-W-N-G-Y-Y-T-T-H-H-F-D-Y (residues 99-115 of SEQ ID NO:46) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein:

the substitution of E at position 1 is selected from the group consisting of D and V;

the substitution of P at position 2 is selected from the group consisting of S and T;

the substitution of N at position 3 is selected from the group consisting of S, T, and H;

the substitution of D at position 4 is selected from the group consisting of E and A;

the substitution of Y at position 10 is F;

the substitution of T at position 11 is selected from the group consisting of A, S, D, P, N, C, and V;

the substitution of H at position 13 is selected from the group consisting of D, Q, N, and L;

the substitution of H at position 14 is selected from the group consisting of D, Y, and N;

the substitution of F at position 15 is selected from the group consisting of L and Y; and

the substitution of Y at position 17 is selected from the group consisting of S, L, N, F, C, I, H, A, and D;

CDR-L1 has an amino acid sequence R-A-S-Q-N-I-G-S-A-L-H (residues 24-34 of SEQ ID NO:47) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein:

the substitution of R at position 1 is W;

the substitution of A at position 2 is V;

the substitution of N at position 5 is selected from the group consisting of D, E, A, and I;

the substitution of G at position 7 is selected from the group consisting of D and E;

the substitution of S at position 8 is selected from the group consisting of Y, A, E, F, T, and G; and

the substitution of A at position 9 is selected from the group consisting of E, D, S, and G;

CDR-L2 has an amino acid sequence: Y-A-S-Q-S-I-S (residues 50-56 of SEQ ID NO:47) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein:

the substitution of Q at position 4 is selected from the group consisting of H, Y, E, N, S, and W;

the substitution of S at position 5 is selected from the group consisting of P and C;

the substitution of I at position 6 is selected from the group consisting of V, T, N, A, M, L, G, S, F, P, and Q; and

the substitution of S at position 7 is P; and

CDR-L3 has an amino acid sequence: H-Q-S-T-S-L-P-H-T (residues 89-97 of SEQ ID NO:47) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein;

the substitution of S at position 3 is selected from the group consisting of T and G;

the substitution of T at position 4 is selected from the group consisting of D, A, Y, S, F, N, I, E, and M;

the substitution of S at position 5 is selected from the group consisting of D, N, G, I, T, F, Y, W, C, E, R, V, L, and M;

the substitution of H at position 8 is selected from the group consisting of Y, Q, F, I, V, D, and N; and

the substitution of T at position 9 is selected from the group consisting of S, A, I, N, and L; and

wherein said substitution of at least one amino acid residue does not inhibit the ability of said antibody or antigen binding portion thereof to bind human IL-17.

2. The antibody or antigen binding portion thereof according to claim 1 , wherein the CDRs are selected from the group consisting of:

SYGIS, residues 31-35 of SEQ ID NO:359 (CDR-H1),

SYGIC, residues 31-35 of SEQ ID NO:362 (CDR-H1),

SYGIV, residues 31-35 of SEQ ID NO:363 (CDR-H1),

GYGIS, residues 31-35 of SEQ ID NO:368 (CDR-H1),

TYGIS, residues 31-35 of SEQ ID NO:372 (CDR-H1),

GYGTS, residues 31-35 of SEQ ID NO:383 (CDR-H1),

GYGIG, residues 31-35 of SEQ ID NO:389 (CDR-H1),

SYGIG, residues 31-35 of SEQ ID NO:394 (CDR-H1),

SYGFS, residues 31-35 of SEQ ID NO:405 (CDR-H1),

SYGYN, residues 31-35 of SEQ ID NO:406 (CDR-H1),

TYGMN, residues 31-35 of SEQ ID NO:408 (CDR-H1),

SYGFG, residues 31-35 of SEQ ID NO:409 (CDR-H1),

SYGTS, residues 31-35 of SEQ ID NO:430 (CDR-H1),

SYCTS, residues 31-35 of SEQ ID NO:431 (CDR-H1),

SYSTS, residues 31-35 of SEQ ID NO:432 (CDR-H1),

SYVIS, residues 31-35 of SEQ ID NO:439 (CDR-H1),

VYGFS, residues 31-35 of SEQ ID NO:440 (CDR-H1),

TYGFS, residues 31-35 of SEQ ID NO:441 (CDR-H1),

SYVFS, residues 31-35 of SEQ ID NO:442 (CDR-H1),

SYGVS, residues 31-35 of SEQ ID NO:443 (CDR-H1),

SYDFS, residues 31-35 of SEQ ID NO:445 (CDR-H1),

GYDFS, residues 31-35 of SEQ ID NO:447 (CDR-H1),

SYIIS, residues 31-35 of SEQ ID NO:452 (CDR-H1),

SYGYS, residues 31-35 of SEQ ID NO:453 (CDR-H1),

SYDYS, residues 31-35 of SEQ ID NO:457 (CDR-H1),

GYVYS, residues 31-35 of SEQ ID NO:460 (CDR-H1),

RYDFS, residues 31-35 of SEQ ID NO:464 (CDR-H1),

SYVVS, residues 31-35 of SEQ ID NO:468 (CDR-H1),

SYGFH, residues 31-35 of SEQ ID NO:469 (CDR-H1),

GITTFFGITDYAQKFQG, residues 50-66 of SEQ ID NO:359 (CDR-H2),

GITNFFGWTDYAQKFQG, residues 50-66 of SEQ ID NO:360 (CDR-H2),

GITNFFGAVDYAQKFQG, residues 50-66 of SEQ ID NO:361 (CDR-H2),

GITNFFGTTDYAQKFQG, residues 50-66 of SEQ ID NO:362 (CDR-H2),

GITTFFGATDYAQKFQG, residues 50-66 of SEQ ID NO:363 (CDR-H2),

GITIFFGTVDYAQKFQG, residues 50-66 of SEQ ID NO:366 (CDR-H2),

GITHFFGTVDYAQKFQG, residues 50-66 of SEQ ID NO:367 (CDR-H2),

GITPFFGWADYAQKFQG, residues 50-66 of SEQ ID NO:368 (CDR-H2),

GITPFFGWTDYAQKFQG, residues 50-66 of SEQ ID NO:370 (CDR-H2),

GITHFFGSTDYAQKFQG, residues 50-66 of SEQ ID NO:374 (CDR-H2),

GITLFFGTVDYAQKFQG, residues 50-66 of SEQ ID NO:378 (CDR-H2),

GITLFFGISDYAQKFQG, residues 50-66 of SEQ ID NO:380 (CDR-H2),

GITNFFGMEDYAQKFQG, residues 50-66 of SEQ ID NO:382 (CDR-H2),

GITHFFGAVDYAQKFQG, residues 50-66 of SEQ ID NO:383 (CDR-H2),

GITNFFGIVDYAQKFQG, residues 50-66 of SEQ ID NO:387 (CDR-H2),

GITPFFGFADYAQKFQG, residues 50-66 of SEQ ID NO:389 (CDR-H2),

GVTTFFGFADYAQKFQG, residues 50-66 of SEQ ID NO:390 (CDR-H2),

GITTFFGVADYAQKFQGR, residues 50-66 of SEQ ID NO:391 (CDR-H2),

GITHFFGMTDYAQKFQG, residues 50-66 of SEQ ID NO:392 (CDR-H2),

GITTFFGTTDYAQKFQG, residues 50-66 of SEQ ID NO:393 (CDR-H2),

GITNFFGVEDYAQKFQG, residues 50-66 of SEQ ID NO:394 (CDR-H2),

GITHFFGISDYAQKFQG, residues 50-66 of SEQ ID NO:395 (CDR-H2),

GITNFFGIRDYAQKFQG, residues 50-66 of SEQ ID NO:396 (CDR-H2),

GITVFFGTADYAQKFQG, residues 50-66 of SEQ ID NO:397 (CDR-H2),

GITLFFGTTDYAQKFQG, residues 50-66 of SEQ ID NO:398 (CDR-H2),

GITHFFGMVDYAQKFQG, residues 50-66 of SEQ ID NO:399 (CDR-H2),

GITNFFGSTDYAQKFQG, residues 50-66 of SEQ ID NO:401 (CDR-H2),

GITHFFGITDYAQKFQG, residues 50-66 of SEQ ID NO:403 (CDR-H2),

GITVFFGHVYYAQKFQG, residues 50-66 of SEQ ID NO:405 (CDR-H2),

GITPFFGTADYAQKFQG, residues 50-66 of SEQ ID NO:406 (CDR-H2),

GITPFFGLADYAQKFQG, residues 50-66 of SEQ ID NO:407 (CDR-H2),

GITPFFGIADYAQKFQG, residues 50-66 of SEQ ID NO:409 (CDR-H2),

GITPILGTANYAQKFQG, residues 50-66 of SEQ ID NO:410 (CDR-H2),

GITPILGTANYAQKFQD, residues 50-66 of SEQ ID NO:421 (CDR-H2),

GITFFFGAADYAQKFQG, residues 50-66 of SEQ ID NO:429 (CDR-H2),

GITHFFGTTDYAQKFQG, residues 50-66 of SEQ ID NO:430 (CDR-H2),

GITHFFGSADYAQKFQG, residues 50-66 of SEQ ID NO:431 (CDR-H2),

GITHFFGTADYAQKFQG, residues 50-66 of SEQ ID NO:432 (CDR-H2),

GITHFFLTTDYAQKFQG, residues 50-66 of SEQ ID NO:435 (CDR-H2),

GITHMFATTDYAQKFQG, residues 50-66 of SEQ ID NO:436 (CDR-H2),

GITPFLGATDYAQKFQG, residues 50-66 of SEQ ID NO:437 (CDR-H2),

GITPFFGFIDYAQKFQG, residues 50-66 of SEQ ID NO:438 (CDR-H2),

GITPFFGTVDYAQKFQG, residues 50-66 of SEQ ID NO:439 (CDR-H2),

GITPFLGTVDYAQKFQG, residues 50-66 of SEQ ID NO:440 (CDR-H2),

GITTFLGTVNYAQKFQG, residues 50-66 of SEQ ID NO:441 (CDR-H2),

GITPLLGISDYAQKFQG, residues 50-66 of SEQ ID NO:442 (CDR-H2),

GITTILGTSDYAQKFQG, residues 50-66 of SEQ ID NO:443 (CDR-H2),

GITPIFGTGDYAQKFQG, residues 50-66 of SEQ ID NO:444 (CDR-H2),

GITTFFESADYAQKFQG, residues 50-66 of SEQ ID NO:445 (CDR-H2),

GITTFFGLADYAQKFQG, residues 50-66 of SEQ ID NO:446 (CDR-H2),

GITPFFGSAYYAQKFQG, residues 50-66 of SEQ ID NO:447 (CDR-H2),

GITPFFGSTDYAQKFQG, residues 50-66 of SEQ ID NO:450 (CDR-H2),

GITPFFGIVNYAQKFQG, residues 50-66 of SEQ ID NO:457 (CDR-H2),

GITTFFGASTYAQKFQG, residues 50-66 of SEQ ID NO:458 (CDR-H2),

GITSFFGTEDYAQKFQG, residues 50-66 of SEQ ID NO:459 (CDR-H2),

GITPFLGTAIYAQKFQG, residues 50-66 of SEQ ID NO:461 (CDR-H2),

GITPILGTENYAQKFQG, residues 50-66 of SEQ ID NO:462 (CDR-H2),

GITPFLGMSSYAQKFQG, residues 50-66 of SEQ ID NO:463 (CDR-H2),

GITPFLGTSNYAQKFQG, residues 50-66 of SEQ ID NO:464 (CDR-H2),

GITPFLGFSNYAQKFQG, residues 50-66 of SEQ ID NO:465 (CDR-H2),

GITPFLGTADYAQKFQG, residues 50-66 of SEQ ID NO:466 (CDR-H2),

GITTFLGTVVYAQKFQG, residues 50-66 of SEQ ID NO:467 (CDR-H2),

GITPFFGTDNYAQKFQG, residues 50-66 of SEQ ID NO:469 (CDR-H2),

GITPFFGLGTYAQKFQG, residues 50-66 of SEQ ID NO:470 (CDR-H2),

GITPFFGAANYAQKFQG, residues 50-66 of SEQ ID NO:471 (CDR-H2),

DPNEFWNGYYATHDFDY, residues 99-115 of SEQ ID NO:359 (CDR-H3),

DPNEFWNGYYATHDFDI, residues 99-115 of SEQ ID NO:364 (CDR-H3),

DPNEFWNGYYDTHDFDS, residues 99-115 of SEQ ID NO:365 (CDR-H3),

DPNEFWNGYYNTHDFDY, residues 99-115 of SEQ ID NO:366 (CDR-H3),

DPNEFWNGYYDTHDLDY, residues 99-115 of SEQ ID NO:367 (CDR-H3),

DPNEFWNGYYDTHHFDY, residues 99-115 of SEQ ID NO:368 (CDR-H3),

VPNEFWNGYYATDYFDN, residues 99-115 of SEQ ID NO:372 (CDR-H3),

EPNEFWNGYYTTHDFDS, residues 99-115 of SEQ ID NO:373 (CDR-H3),

VPNEFWNGYYATQDFDY, residues 99-115 of SEQ ID NO:375 (CDR-H3),

VPNEFWNGYYATDYFDY, residues 99-115 of SEQ ID NO:376 (CDR-H3),

EPNEFWNGYYSTHDFDY, residues 99-115 of SEQ ID NO:378 (CDR-H3),

EPNEFWNGYYATHDFDY, residues 99-115 of SEQ ID NO:379 (CDR-H3),

EPNEFWNGYYTTHDFDA, residues 99-115 of SEQ ID NO:381 (CDR-H3),

DPHEFWNGYYATHDFDY, residues 99-115 of SEQ ID NO:384 (CDR-H3),

DPNEFWNGYYSTHDFDS, residues 99-115 of SEQ ID NO:389 (CDR-H3),

EPNEFWNGYFATNDFDY, residues 99-115 of SEQ ID NO:402 (CDR-H3),

EPNDFWNGYYDTHDFDS, residues 99-115 of SEQ ID NO:403 (CDR-H3),

ESSEFWNGYYCTQDFDL, residues 99-115 of SEQ ID NO:406 (CDR-H3),

ESSEFWNGYYVTNDFDY, residues 99-115 of SEQ ID NO:409 (CDR-H3),

ESNEFWNGYYPTLDLDS, residues 99-115 of SEQ ID NO:410 (CDR-H3),

ESNEFWNGYYPTQDYDF, residues 99-115 of SEQ ID NO:411 (CDR-H3),

ESSAFWNGYYNTNDLDY, residues 99-115 of SEQ ID NO:412 (CDR-H3),

ESTEFWNGYYNTNDYDN, residues 99-115 of SEQ ID NO:413 (CDR-H3),

ESNDFWNGYYTTDDFDY, residues 99-115 of SEQ ID NO:414 (CDR-H3),

ESNDFWNGYYTTDDLDY, residues 99-115 of SEQ ID NO:415 (CDR-H3),

ESNDFWNGYYTTDDFDC, residues 99-115 of SEQ ID NO:416 (CDR-H3),

VPNEFWNGYFPTQDFDY, residues 99-115 of SEQ ID NO:417 (CDR-H3),

ETNEFWNGYFPTQDFDY, residues 99-115 of SEQ ID NO:418 (CDR-H3),

EPNEFWNGYFPTQDFDY, residues 99-115 of SEQ ID NO:419 (CDR-H3),

EPNEFWNGYFPTLDFDC, residues 99-115 of SEQ ID NO:420 (CDR-H3),

EPNDFWNGYYATDNFDY, residues 99-115 of SEQ ID NO:422 (CDR-H3),

EPNDFWNGYYSTDHFDC, residues 99-115 of SEQ ID NO:423 (CDR-H3),

VPNDFWNGYFATDYFDD, residues 99-115 of SEQ ID NO:424 (CDR-H3),

EPNDFWNGYFATDHFDF, residues 99-115 of SEQ ID NO:425 (CDR-H3),

EPNDFWNGYYDTDHFDY, residues 99-115 of SEQ ID NO:426 (CDR-H3),

DPNEFWNGYYATHDFDH, residues 99-115 of SEQ ID NO:427 (CDR-H3),

EPNEFWNGYYSTDHFDY, residues 99-115 of SEQ ID NO:428 (CDR-H3),

EPNDFWNGYYTTHHFDY, residues 99-115 of SEQ ID NO:429 (CDR-H3),

RASQIIGSELH, residues 24-34 of SEQ ID NO:473 (CDR-L1),

RASQDIGSELH, residues 24-34 of SEQ ID NO:474 (CDR-L1),

RASQNIGSELH, residues 24-34 of SEQ ID NO:477 (CDR-L1),

RASQNIGSALH, residues 24-34 of SEQ ID NO:479 (CDR-L1),

RASQDIGSALH, residues 24-34 of SEQ ID NO:488 (CDR-L1),

RASQDIGAALH, residues 24-34 of SEQ ID NO:491 (CDR-L1),

RASQNIGSSLH, residues 24-34 of SEQ ID NO:492 (CDR-L1),

RASQDIGYELH, residues 24-34 of SEQ ID NO:497 (CDR-L1),

RASQEIGFALH, residues 24-34 of SEQ ID NO:499 (CDR-L1),

RASQNIGAELH, residues 24-34 of SEQ ID NO:500 (CDR-L1),

RASQDIGSGLH, residues 24-34 of SEQ ID NO:505 (CDR-L1),

RASQDIGSDLH, residues 24-34 of SEQ ID NO:506 (CDR-L1),

RASQDIDSDLH, residues 24-34 of SEQ ID NO:507 (CDR-L1),

RASQDIGEALH, residues 24-34 of SEQ ID NO:516 (CDR-L1),

RASQEIGASLH, residues 24-34 of SEQ ID NO:517 (CDR-L1),

RASQDIGGELH, residues 24-34 of SEQ ID NO:518 (CDR-L1),

RASQDIETELH, residues 24-34 of SEQ ID NO:519 (CDR-L1),

RASQNIGSDLH, residues 24-34 of SEQ ID NO:520 (CDR-L1),

RASQNIGYELH, residues 24-34 of SEQ ID NO:521 (CDR-L1),

RASQNIGTELH, residues 24-34 of SEQ ID NO:522 (CDR-L1),

RASQNIGSGLH, residues 24-34 of SEQ ID NO:530 (CDR-L1),

RASQNIDSELH, residues 24-34 of SEQ ID NO:533 (CDR-L1),

RASQNIDSDLH, residues 24-34 of SEQ ID NO:535 (CDR-L1),

RASQNIGEELH, residues 24-34 of SEQ ID NO:537 (CDR-L1),

RASQAIGSELH, residues 24-34 of SEQ ID NO:539 (CDR-L1),

YASHSIS, residues 50-56 of SEQ ID NO:473 (CDR-L2),

YASHSGS, residues 50-56 of SEQ ID NO:476 (CDR-L2),

YASWSQS, residues 50-56 of SEQ ID NO:477 (CDR-L2),

YASNSIS, residues 50-56 of SEQ ID NO:478 (CDR-L2),

YASQSIS, residues 50-56 of SEQ ID NO:479 (CDR-L2),

YASHSVS, residues 50-56 of SEQ ID NO:489 (CDR-L2),

YASYSVS, residues 50-56 of SEQ ID NO:490 (CDR-L2),

YASHSNP, residues 50-56 of SEQ ID NO:491 (CDR-L2),

YASYPIS, residues 50-56 of SEQ ID NO:493 (CDR-L2),

YASHSNS, residues 50-56 of SEQ ID NO:495 (CDR-L2),

YASESMS, residues 50-56 of SEQ ID NO:496 (CDR-L2),

YASYSSS, residues 50-56 of SEQ ID NO:498 (CDR-L2),

YASHSTS, residues 50-56 of SEQ ID NO:502 (CDR-L2),

YASHSMS, residues 50-56 of SEQ ID NO:504 (CDR-L2),

YASYSTS, residues 50-56 of SEQ ID NO:509 (CDR-L2),

YASESIS, residues 50-56 of SEQ ID NO:510 (CDR-L2),

YASHSAS, residues 50-56 of SEQ ID NO:511 (CDR-L2),

YASESGS, residues 50-56 of SEQ ID NO:513 (CDR-L2),

YASSSTS, residues 50-56 of SEQ ID NO:514 (CDR-L2),

YASSSLS, residues 50-56 of SEQ ID NO:515 (CDR-L2),

YASHCIS, residues 50-56 of SEQ ID NO:522 (CDR-L2),

YASESVS, residues 50-56 of SEQ ID NO:524 (CDR-L2),

YASYSIS, residues 50-56 of SEQ ID NO:530 (CDR-L2),

YASSSIS, residues 50-56 of SEQ ID NO:532 (CDR-L2),

YASSSPS, residues 50-56 of SEQ ID NO:537 (CDR-L2),

HQSYDLPHT, residues 89-97 of SEQ ID NO:473 (CDR-L3),

HQSYDLPYT, residues 89-97 of SEQ ID NO:474 (CDR-L3),

HQSYWLPNT, residues 89-97 of SEQ ID NO:475 (CDR-L3),

HQSYNLPIT, residues 89-97 of SEQ ID NO:476 (CDR-L3),

HQSMSLPHT, residues 89-97 of SEQ ID NO:478 (CDR-L3),

HQSTSLPHT, residues 89-97 of SEQ ID NO:479 (CDR-L3),

HQGTSLPHT, residues 89-97 of SEQ ID NO:486 (CDR-L3),

HQSDILPHT, residues 89-97 of SEQ ID NO:489 (CDR-L3),

HQSDILPQT, residues 89-97 of SEQ ID NO:491 (CDR-L3),

HQSDFLPHT, residues 89-97 of SEQ ID NO:492 (CDR-L3),

HQSDDLPYT, residues 89-97 of SEQ ID NO:494 (CDR-L3),

HQSSWLPHT, residues 89-97 of SEQ ID NO:495 (CDR-L3),

HQSS#LPHS, residues 89-97 of SEQ ID NO:496 (CDR-L3),

HQSSELPHT, residues 89-97 of SEQ ID NO:497 (CDR-L3),

HQSSCLPHT, residues 89-97 of SEQ ID NO:498 (CDR-L3),

HQTEELPYT, residues 89-97 of SEQ ID NO:499 (CDR-L3),

HQTDRLPYS, residues 89-97 of SEQ ID NO:500 (CDR-L3),

HQTFSLPYT, residues 89-97 of SEQ ID NO:501 (CDR-L3),

HQTDSLPYT, residues 89-97 of SEQ ID NO:502 (CDR-L3),

HQTSDLPYT, residues 89-97 of SEQ ID NO:503 (CDR-L3),

HQTNSLPYT, residues 89-97 of SEQ ID NO:504 (CDR-L3),

HQTDWLPYT, residues 89-97 of SEQ ID NO:505 (CDR-L3),

HQTFNLPYT, residues 89-97 of SEQ ID NO:507 (CDR-L3),

HQTAYLPQT, residues 89-97 of SEQ ID NO:508 (CDR-L3),

HQTDGLPYT, residues 89-97 of SEQ ID NO:509 (CDR-L3),

HQTTLLPYT, residues 89-97 of SEQ ID NO:511 (CDR-L3),

HQGFSLPHT, residues 89-97 of SEQ ID NO:512 (CDR-L3),

HQSFCLPYT, residues 89-97 of SEQ ID NO:513 (CDR-L3),

HQSTSLPYT, residues 89-97 of SEQ ID NO:514 (CDR-L3),

HQSDYLPYT, residues 89-97 of SEQ ID NO:515 (CDR-L3),

HQSDWLPYT, residues 89-97 of SEQ ID NO:516 (CDR-L3),

HQSDGLPYT, residues 89-97 of SEQ ID NO:517 (CDR-L3),

HQSNDLPYT, residues 89-97 of SEQ ID NO:518 (CDR-L3),

HQTYGLPYT, residues 89-97 of SEQ ID NO:519 (CDR-L3),

HQSMGLPYT, residues 89-97 of SEQ ID NO:520 (CDR-L3),

HQSFTLPYT, residues 89-97 of SEQ ID NO:521 (CDR-L3),

HQSESLPHT, residues 89-97 of SEQ ID NO:522 (CDR-L3),

HQSDTLPHT, residues 89-97 of SEQ ID NO:523 (CDR-L3),

HQSTNLPYT, residues 89-97 of SEQ ID NO:524 (CDR-L3),

HQSSILPHT, residues 89-97 of SEQ ID NO:525 (CDR-L3),

HQSTWLPYT, residues 89-97 of SEQ ID NO:526 (CDR-L3),

HQSAFLPYI, residues 89-97 of SEQ ID NO:527 (CDR-L3),

HQSISLPQT, residues 89-97 of SEQ ID NO:528 (CDR-L3),

HQSASLPIT, residues 89-97 of SEQ ID NO:529 (CDR-L3),

HQSAYLPYT, residues 89-97 of SEQ ID NO:530 (CDR-L3),

HQSAVLPDT, residues 89-97 of SEQ ID NO:531 (CDR-L3),

HQSSDLPYT, residues 89-97 of SEQ ID NO:532 (CDR-L3),

HQSFSLPYT, residues 89-97 of SEQ ID NO:533 (CDR-L3),

HQSAFLPYT, residues 89-97 of SEQ ID NO:534 (CDR-L3),

HQSYSLPFN, residues 89-97 of SEQ ID NO:535 (CDR-L3),

HQSYMLPYS, residues 89-97 of SEQ ID NO:536 (CDR-L3),

HQSFSLPVT, residues 89-97 of SEQ ID NO:537 (CDR-L3),

HQSISLPYT, residues 89-97 of SEQ ID NO:538 (CDR-L3),

And

HQSASLPYT, residues 89-97 of SEQ ID NO:539 (CDR-L3).

3. The antibody or antigen binding portion thereof according to claim 1 , wherein the antigen binding domain comprises a heavy chain variable region (VH) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:46 and SEQ ID NOS:359-472.

4. The antibody or antigen binding portion thereof according to claim 1 , wherein the antigen binding domain comprises a light chain variable region (VL) comprising an amino acid sequence selected from the group consisting of SEQ ID NO:47, SEQ ID NO:553, and SEQ ID NOS:473-539.

5. The antibody or antigen binding portion thereof according to claim 1 , further comprising a heavy chain immunoglobulin constant domain comprising a human IgM constant domain, a human IgG1 constant domain, a human IgG2 constant domain, a human IgG3 constant domain, a human IgG4 constant domain, a human IgE constant domain, or a human IgA constant domain.

6. The antibody or antigen binding portion thereof according to claim 5 , wherein the heavy chain immunoglobulin constant domain is the human IgG1 constant domain.

7. The antibody or antigen binding portion thereof according to claim 6 , wherein the human IgG1 constant domain comprises the amino acid sequence of SEQ ID NO:3 or SEQ ID NO:4.

8. The antibody or antigen binding portion thereof according to claim 1 , further comprising a light chain immunoglobulin constant domain comprising a human Ig kappa constant domain or a human Ig lambda constant domain.

9. The antibody or antigen binding portion thereof according to claim 8 , wherein the human Ig kappa constant domain comprises the amino acid sequence of SEQ ID NO:5.

10. The antibody or antigen binding portion thereof according to claim 8 , wherein the human Ig lambda constant domain comprises the amino acid sequence of SEQ ID NO:6.

11. The antibody or antigen binding portion thereof according to claim 1 , wherein the antibody or antigen binding portion thereof is an immunoglobulin molecule, an scFv, a monoclonal antibody, a human antibody, a humanized antibody, an affinity matured antibody, a chimeric antibody, a Fab fragment, an Fab′ fragment, an F(ab′) 2 , an Fv, or a disulfide linked Fv.

12. The antibody or antigen binding portion thereof according to claim 11 , wherein the antibody or antigen binding portion thereof is a human antibody.

13. The antibody or antigen binding portion thereof according to claim 1 , wherein the antibody or antigen binding portion thereof is capable of causing an increase or decrease in the magnitude of a biological function of IL-17, compared to the magnitude of the biological function of IL-17 observed in the absence of the antibody or antigen binding portion thereof.

14. The antibody or antigen binding portion thereof according to claim 1 , wherein the antibody or antigen binding portion thereof neutralizes a biological function of IL-17.

15. The antibody or antigen binding portion thereof according to claim 13 , wherein the IL-17 is pro-human IL-17, mature-human IL-17, or truncated-human IL-17.

16. The antibody or antigen binding portion thereof according to claim 14 , wherein the antibody or antigen binding portion thereof diminishes the ability of IL-17 to bind to its receptor.

17. The antibody or antigen binding portion thereof according to claim 16 , wherein the IL-17 is pro-human IL-17, mature-human IL-17, or truncated-human IL-17.

18. The antibody or antigen binding portion thereof according to claim 13 , wherein the antibody or antigen binding portion thereof has a dissociation constant (K D ) of at most about 10 −7 M.

19. The antibody or antigen binding portion thereof according to claim 13 , wherein the antibody or antigen binding portion thereof has an on rate constant (K on ) of at least about 10 2 M −1 s −1 .

20. The antibody or antigen binding portion thereof according to claim 13 , wherein the antibody or antigen binding portion thereof has an off rate (K off ) of at most about 10 −3 s −1 .

21. The antibody or antigen binding portion thereof according to claim 1 , wherein the antibody or antigen binding portion thereof is conjugated to a detectable label.

22. The antibody or antigen binding portion thereof according to claim 21 , wherein the detectable label is selected from the group consisting of a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, and a biotin.

23. The antibody or antigen binding portion thereof according to claim 1 , wherein the antibody or antigen binding portion thereof is conjugated to a therapeutic or cytotoxic agent.

24. The antibody or antigen binding portion thereof according to claim 23 , wherein the therapeutic or cytotoxic agent is selected from the group consisting of an anti-metabolite, an alkylating agent, an antibiotic, a growth factor, a cytokine, an anti-angiogenic agent, an anti-mitotic agent, an anthracycline, a toxin, and an apoptotic agent.

25. The antibody or antigen binding portion thereof according to claim 1 , wherein the antibody or antigen binding portion thereof is crystallized.

26. The crystallized antibody or antigen binding portion thereof according to claim 25 , wherein the crystallized antibody or antigen binding portion thereof is a carrier-free pharmaceutical controlled release crystal.

27. A composition for the release of a crystallized antibody or antigen binding portion thereof that binds IL-17, the composition comprising:

(a) a formulation, wherein the formulation comprises a crystallized antibody or antigen binding portion thereof according to claim 25 and optionally an additional ingredient comprising an agent selected from the group consisting of albumin, sucrose, trehalose, lactitol, gelatin, hydroxypropyl-β-cyclodextrin, methoxypolyethylene glycol, and polyethylene glycol; and

(b) at least one polymeric carrier.

28. The composition according to claim 27 , wherein the polymeric carrier comprises one or more polymers selected from the group consisting of a poly(acrylic acid), a poly(cyanoacrylate), a poly(amino acid), a poly(anhydride), a poly(depsipeptide), a poly(ester), a poly(lactic acid), a poly(lactic-co-glycolic acid) or PLGA, a poly(b-hydroxybutryate), a poly(caprolactone), a poly(dioxanone); a poly(ethylene glycol), a poly((hydroxypropyl)methacrylamide, a poly[(organo)phosphazene], a poly(ortho ester), a poly(vinyl alcohol), a poly(vinylpyrrolidone), a maleic anhydride-alkyl vinyl ether copolymer, a pluronic polyol, an albumin, an alginate, a cellulose, a cellulose derivative, a collagen, a fibrin, a gelatin, a hyaluronic acid, an oligosaccharide, a glycaminoglycan, a sulfated polysaccharide, and a blend and a copolymer thereof.

29. A pharmaceutical composition comprising the antibody or antigen binding portion thereof according to claim 1 , and a pharmaceutically acceptable carrier.

30. The pharmaceutical composition according to claim 29 , further comprising at least one additional therapeutic agent for treating a disorder in which IL-17 activity is detrimental.

31. The pharmaceutical composition according to claim 30 , wherein the additional agent is selected from the group consisting of an angiogenesis inhibitor, a kinase inhibitor, a co-stimulation molecule blocker, an adhesion molecule blocker, an anti-cytokine antibody or functional binding fragment thereof, methotrexate, a corticosteroid, a cyclosporine, a rapamycin, FK506, and a non-steroidal anti-inflammatory agent.

32. The antibody or antigen binding portion thereof according to claim 1 , wherein antigen binding domain comprises six CDRs: CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein:

CDR-H1 has an amino acid sequence S-Y-G-I-S (residues 31-35 of SEQ ID NO:46) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein:

the substitution of S at position 1 is selected from the group consisting of G and T;

the substitution of I at position 4 is selected from the group consisting of F, T, and Y; and

the substitution of S at position 5 is selected from the group consisting of G and

CDR-H2 has an amino acid sequence G-I-T-P-I-L-G-T-A-N-Y-A-Q-K-F-Q-G (residues 50-66 of SEQ ID NO:46) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein:

the substitution of P at position 4 is selected from the group consisting of H and N;

the substitution of I at position 5 is F;

the substitution of L at position 6 is F;

the substitution of T at position 8 is selected from the group consisting of I, S, W, A, F, and L;

the substitution of A at position 9 is selected from the group consisting of T and V; and

the substitution of N at position 10 is D;

CDR-H3 has an amino acid sequence: E-P-N-D-F-W-N-G-Y-Y-T-T-H-H-F-D-Y (residues 99-115 of SEQ ID NO:46) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein:

the substitution of E at position 1 is selected from the group consisting of D and V;

the substitution of P at position 2 is S;

the substitution of N at position 3 is S;

the substitution of D at position 4 is E; and

the substitution of T at position 11 is selected from the group consisting of A, S, D, and C;

CDR-L1 has an amino acid sequence: R-A-S-Q-N-I-G-S-A-L-H (residues 24-34 of SEQ ID NO:47) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein:

the substitution of N at position 5 is selected from the group consisting of D, E, and A;

the substitution of S at position 8 is A and

the substitution of A at position 9 is selected from the group consisting of E, D, and S;

CDR-L2 has an amino acid sequence: Y-A-S-Q-S-I-S (residues 50-56 of SEQ ID NO:47) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein:

the substitution of Q at position 4 is selected from the group consisting of H, Y, and N; and

the substitution of I at position 6 is selected from the group consisting of V, T, and A; and

CDR-L3 has an amino acid sequence: H-Q-S-T-S-L-P-H-T (residues 89-97 of SEQ ID NO:47) or a modification of said amino acid sequence by substitution of at least one amino acid residue, wherein;

the substitution of S at position 3 is T;

the substitution of T at position 4 is selected from the group consisting of D and A;

the substitution of S at position 5 is selected from the group consisting of G, I, T, Y, and R;

the substitution of H at position 8 is selected from the group consisting of Y and Q; and

the substitution of T at position 9 is S; and

wherein said substitution of at least one amino acid residue does not inhibit the ability of said antibody or antigen binding portion thereof to bind human IL-17.

33. The antibody or antigen binding portion thereof according to claim 32 , wherein the CDRs are selected from the group consisting of: